StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Incyte Corp.
59.72
+1.13%
 

INCY

 

Incyte Corp.

$ 59.72

 
+$0.67 | +1.13%
 
 
Open
$ 59.25
 
 
MKT CAP
$ 13.41B
 
High
$ 59.78
 
 
VOL
$ 1.61M
 
Low
$ 58.07
 
 
AVG VOL
$ 1.64M
 
 
 

INCY Stock Analysis

  Login to display Incyte Corp. (INCY) recommendation from the last 90 days from financial news and social media.
 
 

INCY Total Score

 
 

Strengths

INCY Rewards

 Earnings are forecast to grow

INCY Rewards

 Upgraded on attractively valued

 
 

Chart

 
 

61.5

55.42

55.13

72.86

 
 
1month
3month
6month
1year
 
Total Return
INCY
vs.
S&P500
 

 
1-week Return
-2.10%
 
+1.04%
 
 
5-week Return
-1.52%
 
+4.91%
 
 
10-week Return
-3.52%
 
+7.60%
 
 
 

INCY Risk Level

This Indicator assigning INCY risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
INCY Risk Level
LOW
HIGH

Risk Volatility

 

INCY has Low Risk Level

Click here to check what is your level of risk

 

INCY Analysts Opinion

INCY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

INCY Earnings Sentiment

 Below analyst estimate

INCY Earnings Sentiment

 Reported a weak earnings

 
 

Rating

×
 

Rating

5.00
 

INCY Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.50
 
 

Activity

×
 

Activity

3.80
 
 

Future

×
 

Future

4.00
 

INCY Future Sentiment

 Earnings are forecast to grow

 
 

INCY Analysts Opinion

INCY Analysts opinion is positive and also has improved from the past 3 months

 

INCY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
65%
Buy
Opinion
Trend
Score
Potential
Score
 
 
100%
50%
67%
 
On Track
On Track
On Track
 

INCY Street Opinion 

INCY Street view is bullish and have positive views on the near-term outlook

 

INCY Performance Sentiment

Sentiments overview associated with INCY events and the stock performance.
 
65%
25%
Positive
Negative
13 out of 20
events present
5 out of 20
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

INCY Earnings

The TTM reflects 12-month period, providing review of INCY financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
3,696
3,696
3,395
+4.34%
 
 
Cost of Revenue
255
255
207
+10.99%
 
 
Gross Profit
3,441
3,441
3,188
+3.89%
 
 
Operating Exp
2,791
2,791
2,596
+3.69%
 
 
Operating Inc
650
650
592
+4.78%
 
 
Net Interest Inc
170
170
37
+114.35%
 
 
Interest Exp
3
3
3
0.00%
 
 
Interest Inc
172
172
40
+107.36%
 
 
Other Income
15
15
-100
-
 
 
EPS
1.89
2.67
1.53
+11.14%
 
 
Next Earnings Date: Apr 30, 2024
 
 
Highlights
Last Modify
Price
% Change

 
Approvals
This Week
59.98
-1.67%
 
Concerns
2 Weeks Ago
57.89
-2.44%
 
Weak Earnings
2 Weeks Ago
59.34
+2.59%
 
Agreements
2 Month Ago
59.28
-1.97%
 
Investors Activity
2 Month Ago
65.82
+0.86%
 
 
 
joker
 
 
 
StocksRunner

Explore our INCY Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our INCY Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 

Most Trending

 

-7.16%

 
 
 

+13.55%

 

-2.54%

 
 
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

INCY Rewards

 Earnings are forecast to grow

INCY Rewards

 Upgraded on attractively valued

 
 
 

INCY Risk Level

 
 
 

The Indicator assigning INCY risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
INCY Risk Level
LOW
HIGH

Risk Volatility

 

INCY has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

INCY

 

Incyte Corp.

$ 59.72

 
+$0.67 | +1.13%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 59.25
 
 
MKT CAP
$ 13.41B
 
High
$ 59.78
 
 
VOL
$ 1.61M
 
Low
$ 58.07
 
 
AVG VOL
$ 1.64M
 
 
 

INCY Analysis

  Sign in to view Incyte Corp. (INCY) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

61.5

55.42

55.13

72.86

 
 
1month
3month
6month
1year
 
Total Return
INCY
vs.
S&P500
 

 
1-week Return
-2.10%
 
+1.04%
 
 
5-week Return
-1.52%
 
+4.91%
 
 
10-week Return
-3.52%
 
+7.60%
 
 
 

INCY Analysts Opinion

INCY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

INCY Earnings Sentiment

 Below analyst estimate

INCY Earnings Sentiment

 Reported a weak earnings

 
 

Rating

×
 

Rating

5.00
 

INCY Rating Sentiment

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.50
 
 

Activity

×
 

Activity

3.80
 
 

Future

×
 

Future

4.00
 

INCY Future Sentiment

 Earnings are forecast to grow

 
 

INCY Analysts Opinion

INCY Analysts opinion is positive and also has improved from the past 3 months

 

INCY Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
65%
Buy
Opinion
Trend
Score
Potential
Score
 
 
100%
50%
67%
 
On Track
On Track
On Track
 

INCY Street Opinion 

INCY Street view is bullish and have positive views on the near-term outlook

 
INCY Performance Sentiment
Sentiments overview associated with INCY events and the stock performance.
 
65%
25%
Positive
Negative
13 out of 20
events present
5 out of 20
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

INCY Earnings

The TTM data reflects the most recent 12-month period, providing overview of INCY financial performance.

 
Millions of Dollars
TTM
2023
2022
CAGR
 

 
Total Revenue
3,696
3,696
3,395
+4.34%
 
 
Cost of Revenue
255
255
207
+10.99%
 
 
Gross Profit
3,441
3,441
3,188
+3.89%
 
 
Operating Exp
2,791
2,791
2,596
+3.69%
 
 
Operating Inc
650
650
592
+4.78%
 
 
Net Interest Inc
170
170
37
+114.35%
 
 
Interest Exp
3
3
3
0.00%
 
 
Interest Inc
172
172
40
+107.36%
 
 
Other Income
15
15
-100
-
 
 
EPS
1.89
2.67
1.53
+11.14%
 
 
Next Earnings Date: Apr 30, 2024
 
Highlights
Last Modify
Price
% Change

 
Approvals
This Week
59.98
-1.67%
 
Concerns
2 Weeks Ago
57.89
-2.44%
 
Weak Earnings
2 Weeks Ago
59.34
+2.59%
 
Agreements
2 Month Ago
59.28
-1.97%
 
Investors Activity
2 Month Ago
65.82
+0.86%
 
 
INCY Latest News Feed

Incytes Axatilimab Receives FDA Priority Review For Chronic Graft-Versus-Host Disease Treatment. (RTTNews) - Incyte (INCY) said that the United States Food and Drug Administration has accepted for Priority Review the Biologics License Applicat

Wed Feb 28, 2024

Activity

FDA accepts Incyte application for graft-versus-host disease drug.

Tue Feb 27, 2024

Activity

Jefferies Initiates Coverage of Incyte (INCY) with Buy Recommendation. Fintel reports that on February 23 2024 Jefferies initiated coverage of Incyte (NasdaqGS:INCY) with a Buy recommendation.

Sat Feb 24, 2024

Rating

ish Two Hundred Day Moving Average Cross - INCY. In trading on Thursday shares of Incyte Corporation (Symbol: INCY) crossed above their 200 day moving average of $60.61 changing hands as high as $61.34 per share. Incyte Corporation shares a

Thu Feb 22, 2024

Momentum

JMP cuts Incyte to market perform cites need for acquisition.

Wed Feb 14, 2024

Activity

Commit To Buy Incyte Corporation At $50 Earn 5.6% Annualized Using Options. Investors considering a purchase of Incyte Corporation (Symbol: INCY) stock but cautious about paying the going market price of $58.03/share might benefit from consi

Wed Feb 14, 2024

Activity
Potential

Incytes (INCY) Q4 Earnings & Revenues Fall Shy of Estimates. Incyte Corporation INCY reported fourth-quarter 2023 adjusted earnings of $1.06 per share which missed the Zacks Consensus Estimate

Tue Feb 13, 2024

Earnings

Incyte reports mixed Q4 results. initiates FY24 outlook.

Tue Feb 13, 2024

Earnings

Incyte Q4 Adj EPS Misses Estimates But Revenues Top. (RTTNews) - Incyte Corp. (INCY) on Tuesday reported net income of $201.10 million or $0.89 per share for the fourth quarter sharply higher than $28.46 million or $0.13 per share in the prior-y

Tue Feb 13, 2024

Earnings

Incyte misses quarterly profit estimates due to higher costs. Incyte Corp on Tuesday reported fourth-quarter profit below Wall Street estimates hit by higher costs related to its products such as skin disorder drug Opzelura and forecast weak sal

Tue Feb 13, 2024

Earnings

incy factor-based stock analysis - peter lynch. below is valideas guru fundamental report for incyte corporation (incy). of the 22 guru strategies we follow incy rates highest using our p/e/growth investor model based on the published strategy

Wed Feb 7, 2024

Potential

morphosys jumps amid report novartis in takeover talks. karyopharm surges in sympathy. morphosys ag (nasdaq:mor) adrs soared 58% amid a report that novartis (nyse:nvs) is in advanced talks to acquire the cancer drugmaker. novartis (nvs) appears to be winn

Mon Feb 5, 2024

Activity

relative strength alert for incyte. legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful. one way we can try to measure the level of fear in a given stock is through a technica

Wed Jan 31, 2024

Potential

agilent incyte to collaborate on cdx development programs - quick facts. (rttnews) - agilent technologies inc. (a) announced an agreement with incyte that will bring together agilents expertise in the development of companion diagnostics to supp

Tue Jan 30, 2024

Activity

agilent incyte to collaborate on companion diagnostics development.

Tue Jan 30, 2024

Activity

incy makes notable cross below critical moving average. in trading on monday shares of incyte corporation (symbol: incy) crossed below their 200 day moving average of $62.56 changing hands as low as $62.35 per share. incyte corporation shar

Mon Jan 8, 2024

Momentum

incyte to present at j. p. morgan healthcare conference. webcast at 10:30 am et. (rttnews) - incyte corporation (incy) will present at the 42nd annual j. p. morgan healthcare conference.

Mon Jan 8, 2024

Activity

 
 
 
 
 

Score Tracker

 
 
 
Based on 20 events in the last 90 days from financial news and social media. Last updated Mar 4, 2024 16:31 Wall St. time
 
 

INCY Total Score

 
 
 
 
 
 
 
StocksRunner

Discover INCY Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of INCY. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our INCY Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

INCY Stock trends

INCY Stock performance

INCY Stock analysis

INCY investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker